AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

• Status: Unknown status
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine. Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA is performed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Cytarabine; Daunorubicin; Idarubicin; Mitoxantrone

Criteria

Inclusion Criteria:

• acute promyelocytic leukemia confirmed by detection of t(15;17) and/or PML/RARa

• no contraindication for chemotherapy

• written informed consent

Exclusion Criteria:

• severe comorbidities